Compare BIO-TECHNE Corp (TECH) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Tencent Music Entertainment Group - ADR — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Tencent Music Entertainment Group - ADR trades at $8.82 (market cap $15.69B). The key difference: Tencent Music Entertainment Group - ADR is the larger of the two by market cap, and Tencent Music Entertainment Group - ADR pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| TECH | TME | |
|---|---|---|
Market Cap | $11.24B | $15.69B |
Sector | Health | Media |
52-Week High | $72.29 | $26.36 |
52-Week Low | $43.31 | $8.16 |
Enterprise Value | $11.32B | $12.45B |
Dividend Yield | 0.44% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
TME trades at $9.53, down 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong 2025 revenue of $32.90B and net income of $11.06B, with a P/E of 11.33 indicating reasonable valuation. Recent news highlights institutional buying and strategic moves like the Ximalaya acquisition to bolster ecosystem dominance.
Outlook is cautiously optimistic with a consensus price target of $14.00, offering 47% upside. Risks include competitive pressures and AI-driven copyright challenges, but solid profitability and Tencent backing provide resilience. The stock presents a value opportunity if execution on premiumization continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
